Medtronic announced a spin-off of its diabetes business in May, which will be completed in 2026. Read more on MDT stock here.

Although the company's advancements have influenced contemporary healthcare, its stock presents a more cautious narrative ...

While Medtronic has struggled to keep up with the broader market over the past year, analysts remain fairly upbeat on its ...

The US Court of Appeals for the Federal Circuit recently held that cancellation of a claim during prosecution may give rise to prosecution ...

Medtronic's separation of its Medtronic Diabetes unit into a publicly traded company named MiniMed will be a new beginning ...

Medtronic also disclosed severance for a former SVP, and pay for its median employee, and a slight decrease in global ...

Medtronic's decade-long underperformance stems from stagnant revenue growth, declining margins, and inconsistent returns on ...

All of those factors make Medtronic an excellent pick for income-seeking investors. It should continue rewarding shareholders ...

Abbott and Boston Scientific are among the investors in SetPoint, whose neurostimulation device gained FDA approval last ...

Orchestra BioMed reported that it has secured over $111 million in financing through a series of transactions and ...

Medtronic has long been a committed dividend payer -- and grower. It's been turning itself around after a slump. There's ...

Shares of Medtronic PLC MDT slipped 1.53% to $90.24 Thursday, on what proved to be an all-around poor trading session for the ...